Evidence map›Paper›PMID 36834872›Full record

ReviewInternational journal of molecular sciences2023

Novel Therapeutic Potential of Retinoid-Related Orphan Receptor α in Cardiovascular Diseases.

Yun Chen, Shu-Ping Zhang, Wei-Wei Gong, Yang-Yang Zheng, Jie-Ru Shen, Xiao Liu, Yun-Hui Gu, Jia-Hai Shi, Guo-Liang Meng

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yun ChenDepartment of Pharmacology, School of Pharmacy, Nantong University, Nantong 226001, China.
Shu-Ping ZhangDepartment of Pharmacology, School of Pharmacy, Nantong University, Nantong 226001, China.
Wei-Wei GongDepartment of Pharmacology, School of Pharmacy, Nantong University, Nantong 226001, China.
Yang-Yang ZhengDepartment of Pharmacology, School of Pharmacy, Nantong University, Nantong 226001, China.
Jie-Ru ShenNantong Key Laboratory of Translational Medicine in Cardiothoracic Diseases, Research Institution of Translational Medicine in Cardiothoracic Diseases, Nantong University, Nantong 226001, China.
Xiao LiuNantong Key Laboratory of Translational Medicine in Cardiothoracic Diseases, Research Institution of Translational Medicine in Cardiothoracic Diseases, Nantong University, Nantong 226001, China.
Yun-Hui GuDepartment of Pharmacology, School of Pharmacy, Nantong University, Nantong 226001, China.
Jia-Hai ShiNantong Key Laboratory of Translational Medicine in Cardiothoracic Diseases, Research Institution of Translational Medicine in Cardiothoracic Diseases, Nantong University, Nantong 226001, China.
Guo-Liang MengDepartment of Pharmacology, School of Pharmacy, Nantong University, Nantong 226001, China.ORCID 0000-0002-8523-6543
Nantong University · CN

Funding

Jiangsu College Students' Innovation and Entrepreneurship Training Program 202110304118YNational Natural Science Foundation of China 82270418, 82070280, 82200313, 81770266Natural Science Foundations of Nantong City MS22020006Natural Science Research in Jiangsu Higher Education Institutions 21KJB310014Postgraduate Research & Practice Innovation Program of Jiangsu Province KYCX22_3378Six Talent Peaks Project in Jiangsu Province 2018-WSN-062the "333 Project" of Jiangsu Province 2022-3-16-670
6 · The paper itself

Abstract

The retinoid-related orphan receptor α (RORα) is one subfamily of nuclear hormone receptors (NRs). This review summarizes the understanding and potential effects of RORα in the cardiovascular system and then analyzes current advances, limitations and challenges, and further strategy for RORα-related drugs in cardiovascular diseases. Besides regulating circadian rhythm, RORα also influences a wide range of physiological and pathological processes in the cardiovascular system, including atherosclerosis, hypoxia or ischemia, myocardial ischemia/reperfusion injury, diabetic cardiomyopathy, hypertension, and myocardial hypertrophy. In terms of mechanism, RORα was involved in the regulation of inflammation, apoptosis, autophagy, oxidative stress, endoplasmic reticulum (ER) stress, and mitochondrial function. Besides natural ligands for RORα, several synthetic RORα agonists or antagonists have been developed. This review mainly summarizes protective roles and possible mechanisms of RORα against cardiovascular diseases. However, there are also several limitations and challenges of current research on RORα, especially the difficulties on the transformability from the bench to the bedside. By the aid of multidisciplinary research, breakthrough progress on RORα-related drugs to combat cardiovascular disorder may appear.

Indexed as

Cardiovascular DiseasesDiabetic CardiomyopathiesCardiomegalyHumansNuclear Receptor Subfamily 1, Group F, Member 1Receptors, Cytoplasmic and NuclearRetinoidsNuclear Receptor Subfamily 1, Group F, Member 1Receptors, Cytoplasmic and NuclearRetinoidsRORA protein, humanagonistcardiovascular diseasesligandretinoid-related orphan receptor αstaggerer mutant mice

Identifiers

PMID36834872
PMCPMC9959049
OpenAlexW4319762244

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.